News2020-07-17T11:41:26-04:00
Apr 112022

Halberd Entering the Medical Metaverse(TM)

April 11th, 2022|Categories: Investor News, News, Press Releases|

Jackson Center, PA, April 11, 2022 – Halberd Corporation (OTC PINK:HALB) announces plans to enter the Metaverse by the creation of nonfungible tokens (NFT’s) to monetize certain intellectual properties of the company including but not limited to patents, patents pending, trade secrets, etc. Halberd is currently in negotiations to engage a team of experts in Metaverse with expertise in nonfungible tokens (NFT’s) who can identify growth opportunities by monitoring the evolving marketplace, setting category strategy, ...

Apr 42022

Halberd Continues In-Vitro Successes With Elimination of Protein Linked to Depression

April 4th, 2022|Categories: Investor News, Medical, News, Press Releases|

Jackson Center, PA, April 4, 2022 – Halberd Corporation (OTC PINK:HALB) demonstrated the extracorporeal elimination of C-Reactive Protein from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro.  Halberd, encouraged by its recent success in eliminating all ten of the top antigens associated with PTSD (Post Traumatic Stress Disorder), CTE (Chronic Traumatic Encephalopathy) and numerous other neurodegenerative diseases, expanded their research to address elimination of the disease antigen associated with clinical depression ...

Mar 252022

Halberd Corporation Brief Overview

March 25th, 2022|Categories: Featured, News|

Halberd Corporation Brief Overview Halberd Corporation was re-formed in May 2020.  Noting that Halberd’s unique extracorporeal technological approach is adaptable to many disease states, Halberd’s team of professionals employed its skills, resources and focus to concentrate on developing treatments against some of the world’s more persistent diseases, such as, Alzheimer’s Disease, PTSD, Parkinson’s Disease, epilepsy and other neurodegenerative diseases, sepsis, meningitis, and pandemics, among others.  Except for select trade secrets, Halberd’s technology ...

Mar 162022

Infectious Disease Specialist Will Guide Halberd’s Extracorporeal Elimination of Disease Antigens in Animals and Then Humans

March 16th, 2022|Categories: Featured, Investor News, News, Press Releases|Tags: , |

Jackson Center, PA, March 16, 2022 – Halberd Corporation (OTC-PINK: "HALB") announces its entry into the next stage of research.  To guide it, having successfully eliminated the Top 10 Target Antigens associated with neurodegenerative diseases in vitro, Halberd is pleased to announce the addition of Ravi Venkata Durvasula, M.D., a renowned infectious disease specialist and educator, to its team of technical experts and consultants.  Dr. Durvasula will guide Halberd’s efforts in applying its patented extracorporeal ...

Mar 82022

Halberd Expands Its Technical Expertise With the Addition of Microbiology Professor

March 8th, 2022|Categories: Featured, Investor News, News|Tags: , , , |

Jackson Center, PA, March 8, 2022 – Halberd Corporation (OTC-PINK: "HALB") is pleased to announce Youngstown State University’s (YSU) Dr. Chester R. Cooper has joined its technical team.  Dr. Cooper currently holds the position of Professor, Department of Biological Sciences, at Youngstown State University.  Dr. Cooper has been a valuable resource in Halberd’s work at the university in the area of E. coli testing and analysis over the past several months. Dr. Cooper earned his ...

Mar 12022

Halberd’s COVID-19 Antibody is the Only One In Competitive Tests to Bind to Omicron Variant

March 1st, 2022|Categories: Featured, Investor News, Medical, News|Tags: , , , , , |

Outperforms Approved COVID Antibodies Jackson Center, PA, March 1, 2022 – Halberd Corporation’s (OTC PINK:HALB) previously developed SARS-CoV-2 antibody demonstrated superior binding capability to the SARS-CoV-2 Omicron variant disease antigen.  The Halberd antibody was tested against monoclonal antibodies which are biosimilar to five FDA approved Emergency Use Authorization (EUA) COVID antibodies.  The results are shown on the graph below. On the vertical axis is the Absorbance (a measure of binding capability) of the various monoclonal ...

Go to Top